US court throws out first Actos verdict
This article was originally published in Scrip
The Superior Court of California in Los Angeles has granted a motion by defendant Takeda and thrown out a jury verdict in the first case to come to trial claiming a link between the Japanese firm's diabetes drug Actos (pioglitazone) and bladder cancer.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.
Tislelizumab meets overall survival endpoint in later-line NSCLC at planned interim analysis, but faces exploding competition in the Chinese immuno-oncology sector.